Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study

• Main Authors: Yiting Sun (Author), Liqing Jiang (Author), Ti Wen (Author), Xiaoyu Guo (Author), Xinye Shao (Author), Hui Qu (Author), Xi Chen (Author), Yujia Song (Author), Fang Wang (Author), Xiujuan Qu (Author), Zhi Li (Author)
• Format: Book
• Published: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The programmed death receptor 1 (PD1) and its ligand programmed death receptor ligand 1 (PDL1) are the most widely used immune checkpoints in cancer immunotherapy. The related literature shows the explosive growth trends due to the promising outcomes of tumor regression. The present study aimed to p...